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ABSTRACT: 5-Fluorocytosine (5-FC) was investigated for
the controlled synthesis of cocrystals by applying the pKa rule.
Five cocrystals were designed and developed with adipic,
succinic, terephtalic, benzoic, and malic acids, all exhibiting
negative ΔpKa values ranging from close to zero up to roughly
−1. The synthesized cocrystals were analyzed by single crystal
X-ray diﬀraction, and the observed supramolecular synthons
were compared to the reported structures containing 5-FC. In
the ﬁrst four cocrystals, the intermolecular interactions
between adjacent 5-FC molecules form two diﬀerent homodimers showing R2
2(8) motifs and assembled via complementary
N−H···O and N−H···N hydrogen bonds, respectively. However, in the cocrystal with malic acid (ΔpKa = −0.1), an intermediate
supramolecular synthon pattern between salts and cocrystals is observed. In this crystal packing, the homodimer of 5-FC
molecules held by the N−H···O interactions is preserved, but a new heterodimer is formed between 5-FC and the acid molecule,
such as the ones observed for 5-FC salts. These diﬀerences were analyzed using UNI Force Field Calculations to establish the
intermolecular potentials of the synthons. As an application, we synthesized a cocrystal of 5-FC with 5-ﬂuorouracil. This can be
considered the ﬁrst step toward the application of 5-FC for the design of new tailor-made drugs.
1. INTRODUCTION
Crystal engineering and supramolecular chemistry are emerging
issues in active pharmaceutical ingredients (APIs). Achieving
the ability to explore and predict the occurrence of noncovalent
interactions among APIs and other molecules, such as solvents,
acids, bases, and other substances recognized as safe (GRAS),
for the rational design of pharmaceutical products in the solid
state, exhibiting improved physical and chemical properties, is a
challenge to scientists. Among the solid forms that an API may
exhibit, the class of pharmaceutical cocrystals is noteworthy, i.e.,
solid pharmaceutical compounds containing at least one
molecular API and at least one solid nontoxic cocrystal former
(usually a GRAS compound) interacting with one another
through unique binding interactions; it is a hard task to predict
how the API(s) and the coformer(s) will interact to each other.
This class has presented increasing interest in the last few years
due to its immense ability to form new compounds that do not
alter the pharmacological activity of the API but may improve
its physical properties, not being restricted to binary
compounds, once ternary and quaternary cocrystals may be
designed.1−7
By considering that cocrystal formation is not obvious (it is a
result of a supramolecular study and synthesis), beyond the fact
that pharmaceutical cocrystals have utility (may improve the
physical properties of an API) and are considered a novel
compound (possesses a new chemical composition and an
unpredictable chemical bonding), they are subject to patents.
This possibility opens the door to new commercial
opportunities for an API, oﬀering to the pharmaceutical
industries the beneﬁts of generating a new and exclusive patent
upon a new chemical compound or even of maintaining and
extending its exclusivity, by covering, beforehand, new solid
forms. In this sense, the patent can encompass not only the
initial chemical compound but also its cocrystals through the
creation of a solid-form patent portfolio. As advantage, the path
to patent a cocrystal can be abbreviated in some aspects,
considering that issues such as toxicology and discovery do not
need to be extensively evaluated.8,9
5-Fluorocytosine (4-amino-5-ﬂuoro-1,2-dihydropyrimidin-2-
one, 5-FC, Scheme 1) was synthesized in 1957 as an
antimetabolite drug to be used as an antitumor agent. It was
found to exhibit activity against fungal infections and was
released for this use in 1968. By the discovery of its mechanism
of action, i.e., conversion into 5-ﬂuorouracil (5-FU) by
deamination performed by the enzyme cytosine deaminase
(CD)natural in fungal cells5-FC is being recently
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Scheme 1. Molecular Structure of 5-FC
Article
pubs.acs.org/crystal
© 2014 American Chemical Society 4383 dx.doi.org/10.1021/cg500502j | Cryst. Growth Des. 2014, 14, 4383−4393
employed in gene-directed enzyme prodrug therapy (GDEPT)
to treat cancer. Concerning pharmacokinetics, toxicity, and
drug interactions, 5-FC is a BCS class I drug of small size, high
solubility in water, and high permeability (bioavailability of 76%
− 89%). It exhibits minor side eﬀects, although hepatotoxicity
and bone marrow depression may occur. Nevertheless, normal
mammalian cells do not express CD and are resistant to this
drug, such that over 90% of it is eliminated unchanged in the
urine.10−12
The ﬁrst crystal structure of 5-FC deposited in the
Cambridge Structural Database (CSD)13 was a monohydrate
reported in 1982.14 Since then, 30 ﬁve crystal structures were
reported in the literature, including two polymorphs,15 six
hydrates,15−18 four solvates,15,17 10 salts19−22 and 13
cocrystals.23−25 Nineteen of them crystallize in the monoclinic
crystalline system, 12 in the P21/c (four hydrates, four salts, one
solvate, and three cocrystals), four in the P21/n (two salts, one
solvate, and one polymorph), two in the Cc (one hydrate and
one cocrystal), and one in the C2/c (one cocrystal) space
groups. Twelve crystallize in the triclinic P1 ̅ space group (two
hydrates, one solvate, and nine cocrystals), and one in the
tetragonal P41212 space group (polymorph). From these
numbers, it is possible to observe that neutral state is
predominant for this ﬂuoropyrimidine. Furthermore, it is
worth noting that three salts and eight cocrystals have solvents
introduced into the crystalline arrangement.20−22,24,25
In our previous work,22 we discussed salt formation by the 5-
FC molecules on the basis of a salt/cocrystal continuum
study.26,27 As a follow-up to these studies, here we discuss the
supramolecular synthesis of ﬁve cocrystals of 5-FC containing
adipic, succinic, benzoic, tereftalic, and malic acids as coformers,
aiming to add information to the salt−cocrystal continuum
study, to improve understanding of 5-FC drug−receptor
interactions and, especially, to understand the controlled
synthesis of cocrystals. On the basis of the supramolecular
patterns established by these 5-FC cocrystals, we were able to
design and synthesize a cocrystal involving two APIs, 5-FC and
5-FU, an antineoplastic drug.
2. EXPERIMENTAL SECTION
All reagents were used without additional puriﬁcation.
2.1. Cocrystals Supramolecular Synthesis. Stoichiometric
amounts of 5-FC (Sigma-Aldrich Brazil) with succinic, adipic, benzoic,
terephtalic, and malic acids and 5-FU were employed, using water as
the solvent. The solutions were ﬁltered through a 0.45 μm ﬁlter
(Milipore) and maintained at room temperature, semicovered by
Paraﬁlm until complete slow evaporation of the solvent. The resulting
crystals were selected for single crystal X-ray diﬀraction experiments.
2.2. Single Crystal X-ray Structure Determination. The
crystallographic data for the cocrystals of 5-FC with adipic, succinic,
and terephtalic acids were collected on a Bruker Super-Duo APEX II
CCD diﬀractometer using MoKα radiation (0.71073 Å). For the
cocrystal of 5-FC with 5-FU, Cu Kα radiation was used (1.54178 Å) in
Table 1. Crystallographic Data for the 5-FC Solid Forms S, T, A, M, B, and 5-F
Form S Form A Form T
C4H4FN3O, 1/2 C4H6O4 C4H4FN3O, 1/2 C6H10O4 C4H4FN3O, 1/2 C8H6O4
space group P1̅ space group P1̅ space group P1̅
a (Å) = 4.9209(3) a (Å) = 5.2742(5) a (Å) = 3.6265(3)
b (Å) = 8.6115(5) b (Å) = 6.6650(7) b (Å) = 9.5274(8)
c (Å) = 9.4689(6) c (Å) = 12.8441(13) c (Å) = 13.7902(12)
α (°) = 72.466(3) α (°) = 86.411(6) α (°) = 107.812(5)
β (°) = 75.129(3) β (°) = 80.757(6) β (°) = 92.036(4)
γ (°) = 89.747(3) γ (°) = 71.970(6) γ (°) = 96.844(4)
V (Å3) = 368.64(4) Å3 V (Å3) = 423.72(7) Å3 V (Å3) = 449.09(7) Å3
Z = 2 Z = 2 Z = 2
ρcalc = 1.695 g/cm
3 ρcalc = 1.585 g/cm
3 ρcalc = 1.569 g/cm
3
2572 unique reﬂns 1624 unique reﬂns 2602 unique reﬂns
R(int) = 0.0219 R(int) = 0.0280 R(int) = 0.0302
θmax = 25.00° θmax = 25.80° θmax = 27.50°
R1[I>2σ(I)] = 0.0381 R1[I>2σ(I)] = 0.0476 R1[I>2σ(I)] = 0.0449
wR2 = 0.1153 wR2 = 0.1322 wR2 = 0.1131
S = 1.103 S = 1.122 S = 1.078
Form M Form B Form 5F
C4H4FN3O, C4H6O5 C4H4FN3O, C7H6O2 C4H4FN3O, C4H3FN2O2
space group C2/c space group P21/n space group P21/c
a (Å) = 20.8980(4) a (Å) = 9.0565(2) a (Å) = 15.0176(3)
b (Å) = 14.8590(9) b (Å) = 5.4318(2) b (Å) = 3.5604(1)
c (Å) = 7.244(1) c (Å) = 22.8887(8) c (Å) = 27.3113(4)
β (°) = 107.178(3) β (°) = 92.870(1) β (°) = 138.282(1)
V (Å3) = 2149.1(4) Å3 V (Å3) = 1124.55(6) Å3 V (Å3) = 971.78(4) Å3
Z = 8 Z = 4 Z = 4
ρcalc = 1.639 g/cm
3 ρcalc = 1.484 g/cm
3 ρcalc = 1.772 g/cm
3
2451 unique reﬂns 2306 unique reﬂns 1628 unique reﬂns
R(int) = 0.0547 R(int) = 0.0252 R(int) = 0.0284
θmax = 27.49° θmax = 25.242° θmax = 66.685°
R1[I>2σ(I)] = 0.0729 R1[I>2σ(I)] = 0.0482 R1[I>2σ(I)] = 0.0312
wR2 = 0.1853 wR2 = 0.1212 wR2 = 0.0841
S = 1.010 S = 1.035 S = 1.069
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the same equipment. X-ray diﬀraction data collection (φ scans and ω
scans with κ oﬀsets) for the cocrystals of 5-FC with malic and benzoic
acids were performed on an Enraf-Nonius Kappa-CCD diﬀractometer
(95 mm CCD camera on κ-goniostat) using graphite-monochromated
MoKα radiation (0.71073 Å). For reﬁnement details28−34 see the
Supporting Information.
In all cases, the programs MERCURY (version 2.3)35 and ORTEP-
336 were used also within WinGX v1.70.0132 to prepare the
crystallographic information ﬁle (CIF) and artwork representations
for publication.
The CIFs of the three 5-FC cocrystals were deposited in the
Cambridge Structural Data Base under the codes CCDC 933072
(cocrystal of 5-FC with adipic acid), CCDC 933073 (cocrystal of 5-FC
with succinic acid), CCDC 933074 (cocrystal of 5-FC with terephtalic
acid), CCDC 991413 (cocrystal of 5-FC with 5-FU), CCDC 991431
(cocrystal of 5-FC with malic acid) and CCDC 991584 (cocrystal of 5-
FC with benzoic acid). Copies of these ﬁles may be solicited free of
charge from The Director, CCDC, 12 Union Road, Cambridge, CB2
1EZ, UK, fax: + 44123−336−033; e-mail: deposit@ccdc.cam.ac.uk or
http:www.ccdc.cam.ac.uk.
3. RESULTS
3.1. Structure Determination. We adopt the following
nomenclature for the cocrystals depicted herein: form S
(cocrystal of 5-FC with succinic acid), form T (cocrystal of
5-FC with terephtalic acid), form B (cocrystal of 5-FC with
benzoic acid), form M (cocrystal of 5-FC with malic acid), form
A (cocrystal of 5-FC with adipic acid), and form 5F (cocrystal
of 5-FC with 5-FU). Table 1 exhibits the crystallographic data
for the structures.
3.2. Structural Description. A detailed description of the
structures is depicted below. The main hydrogen-bond metrics
for each cocrystal are listed in Table S1 (Supporting
Information). In Figure 1, an ORTEP-336 view of the
asymmetric unit of each cocrystal is shown. The structure
and data for form 5F will be depicted in a separate section.
Cocrystal of 5-FC with Succinic Acid. The asymmetric unit
of form S (Figure 1) exhibits one 5-FC molecule as well as a
succinic acid, the latter sitting on a crystallographic inversion
center giving just half of this molecule per asymmetric unit.
Bifurcated hydrogen bonds (N41−H41A···O3 and O3−H3···
O21) occur among the acid and two 5-FC molecules (Figure
2a). These interactions lead the 5-FC molecules to interact with
each other forming a R2
2(8) motif37a,b (Figure 2a) assembled via
complementary N41−H41···N3 hydrogen bonds and also
promote the formation of a nonclassical C6−H6···O4 (bond
Figure 1. ORTEP-336 type view of the 5-FC cocrystals. Thermal ellipsoids for forms S, A, and T are at the 50% probability level and for forms M, B,
and 5F at the 30% probability level. Hydrogen atoms are drawn as spheres of arbitrary radii.
Figure 2. (a) Crystal packing diagram of form S. Black dashed lines
indicate hydrogen bonds, (I) refers to the R2
2(8) motif37a,b involving
the N−H···N 5-FC homodimers, (II) to the R22(8) motif
37a,b involving
the N−H···O 5-FC homodimers, and (III) to the R64(40) motif,37a,b
(b) three-dimensional hydrogen-bonded network of form S.
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length of 2.071 Å) one. A second R2
2(8) motif is observed
between the 5-FC molecules, involving complementary N1−
H1···O21 hydrogen bonds, leading to the formation of 1-D
tapes which run parallel on both sides of the acid molecule.
This arrangement of the molecules in the crystal lattice gives
rise to the formation of cavities with graph set R6
4(40) and
constitutes ﬂat layers oﬀset stacked along [1 ̅21]. The stacking
of the layers (Figure 2b) is kept only by van der Waals contacts,
of the types C···O, C···F, and C···N, which results in an
interlayer separation of approximately 3.20 Å to one another
(van der Waals radii38 for C = 1.70 Å, N = 1.55 Å, O = 1.52 Å
and F = 1.47 Å).
Cocrystal of 5-FC with Adipic Acid. The asymmetric unit of
form A (Figure 1) also exhibits one molecule of 5-FC and half
adipic acid since, as mentioned previously, it is sitting on an
inversion center. The crystal packing preserve similar
intermolecular interaction patterns such as the ones found for
form S (Figure 3a): two R2
2(8) motifs, constituted via
complementary N41−H41···N3 and N1−H1···O21 hydrogen
bonds between 5-FC molecules and a bifurcated (N41−
H41A···O3 and O3−H3···O21) interaction between 5-FC
molecule and both carboxyl groups of the acid, also resulting in
the formation of the nonclassical C6−H6···O4 (bond length of
2.109 Å) intermolecular interaction plus a C8−H8···F51 (bond
length of 2.444 Å) one. In this way, the forms S and A exhibit a
similar arrangement of the molecules in the crystal lattice.
However, as a result of the increase in the length of the carbon
chain in the adipic acid, the cavity formed (Figure 3a) possess a
graph set of R6
4(48), and the layers are not as ﬂat as the ones
observed in form S once the adipic acid adopts a zigzag
conformation in its carbon chain. The layers are oﬀset stacked
along [120], and beyond the van der Waals contacts holding
these layers together, there is a nonclassical C9−H9A···F51
(bond length of 2.419 Å) hydrogen bond (Figure 3b).
Cocrystal of 5-FC with Terephtalic Acid. The asymmetric
unit of form T (Figure 1) exhibits one 5-FC and half terephtalic
acid molecule, for the acid is placed on an inversion center as in
forms S and A. As observed in forms S and A, the two 5-FC
ring motifs (Figure 4a) and the two 5-FC−acid hydrogen
bonds (Figure 4a) plus the nonclassical C6−H6···O4 (bond
length of 2.201 Å) are preserved in form T. As a consequence
of the close packing, a nonclassical C10−H10···F51 (bond
length of 2.491 Å) intermolecular interaction overcome. Form
Figure 3. (a) Crystal packing diagram of form A. Black dashed lines
indicate hydrogen bonds, (I) refers to the R2
2(8) motif37a,b involving
the N−H···N 5-FC homodimers, (II) to the R22(8) motif
37a,b involving
the N−H···O 5-FC homodimers, and (III) to the R64(48) motif,37a,b
(b) three-dimensional hydrogen-bonded network of form A.
Figure 4. (a) Crystal packing diagram of form T. Black dashed lines
indicate hydrogen bonds, (I) refers to the R2
2(8) motif37a,b involving
the N−H···N 5-FC homodimers, (II) to the R22(8) motif
37a,b involving
the N−H···O 5-FC homodimers, and (III) to the R64(44) motif,37a,b
(b) three-dimensional hydrogen-bonded network of form T.
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T also exhibits a similar layered pattern stacked along [110].
The cavities (Figure 4a) formed in this crystalline arrangement
adopts a ring graph-set with the R6
4(44) notation, smaller than
the one found in form A. Although both 5-FC and terephtalic
acid molecules adopt a planar conformation, they are not
aligned in the same plane (Figure 4b). The angle between the
plane passing through the non-hydrogen atoms of the 5-FC
molecules and the one passing through the terephtalic acid is
26.66(2)°. The terephtalic molecules are stacked as the 5-FC
ones, in a fashion that π···π interactions take place (centroid−
centroid distance equal to 3.6265(3)Å for both molecules),
being mainly responsible for the maintenance of form T
crystalline packing.
Cocrystal of 5-FC with Benzoic Acid. The asymmetric unit
of form B (Figure 1) exhibits one molecule of 5-FC and one of
benzoic acid. The arrangement of the 5-FC molecules follows
the same pattern observed for form T, with the two 5-FC ring
motifs37a,b (Figure 5a) and the two 5-FC−acid hydrogen bonds
preserved as is the nonclassical C6−H6···O4 (bond length of
2.071 Å). The 1-D tapes of the 5-FC molecules are surrounded
by benzoic acid molecules forming stacked layers sustained only
by van der Waals contacts with an interlayer separation of
approximately 5.432 Å (Figure 5b). The neighboring layers are
twisted 74.25° with respect to each other, forming a
herringbone pattern. This supramolecular pattern arises from
unconventional hydrogen bonds (Table S1 in the Supporting
Information) involving ﬂuorine atoms of the 5-FC and carbon
atoms (C11 and C13) of the benzoic acid molecules (Figure
5a). As is observed in form T, the benzoic acid molecules are
not exactly placed on the same plane of the 1-D tape. However,
the angle between the mean plane deﬁned by the non-hydrogen
atoms of the 5-FC and the non-hydrogen atoms of the benzoic
acid molecule is smaller in form B than in form T, assuming a
value of 20.43°.
Cocrystal of 5-FC with Malic Acid. The asymmetric unit of
form M (Figure 1) exhibits one 5-FC and one molecule of
malic acid. In contrast to the other forms, form M preserves
only the R2
2(8) motif accessed via complementary N1−H1···
O21 hydrogen bonds among the 5-FC molecules, like that
observed in the other cocrystals (Figure 6a). However, a second
R2
2(8) motif is inherent of form M and arises from the
interactions of 5-FC molecules with surrounding malic acid
molecules (O3−H3···N3 and N41−H41B···O4), constituting a
heterodimer (Figure 6a). Additional hydrogen bonds (N41−
H41A···O5 and O7−H7···O21) lead to the formation of ﬂat
layers stacked along the c axis and of a cavity represented by the
R6
4(36) graph-set notation37a,b (Figure 6a). The layers are held
together via O5−H5···O6 hydrogen bonds involving the malic
acid molecules and also via π···π interactions (centroid−
centroid distance equal to 3.495(9)Å) between the rings of the
5-FC molecules (Figure 6b).
4. DISCUSSION
We have conducted cocrystallization experiments with 5-FC
and ﬁve dicarboxylic acids presenting the following pKa values:
4.43 (adipic acid), 4.21 (benzoic acid), 4.16 (succinic acid),
3.52 (terephtalic acid) and 3.40 (malic acid). These acids were
chosen in an attempt to evaluate the extent of proton transfer
to the 5-FC molecules, based on the pKa rule,
26,27,39
contributing to the study of the salt/cocrystal continuum and
providing information related to the capability of predicting and
controlling the synthesis of compounds containing the
ﬂuoropyrimidine group.
As the pKa value for the 5-FC is 3.26, then the respective
values of ΔpKa (pKaacid − pKabase) for adipic, benzoic, succinic,
terephtalic, and malic acids are −1.16, −0.95, −0.9, −0.26, and
−0.14 ranging from close to zero to more negative values.
According to Bhogala et al.,27 for negative values of ΔpKa a
cocrystal formation is expected. One method of verifying
successful cocrystal formation is to calculate the C−O bond
length diﬀerences of the carboxyl groups in the acid molecule,
ΔDC−O. If this variation is small (<0.03 Å), then a salt is
formed. If, however, this diﬀerence is higher than 0.08 Å, then a
cocrystal is formed. For all the structures depicted here, the
ΔDC−O values are above 0.08 Å (form S = 0.117(1) Å, form A =
0.119(3) Å, form T = 0.114(2) Å, form B = 0.121(2) Å, and
form M = 0.109(5) Å), which means that the C−O distances
are not symmetrical, as in the carboxylate anions, evidencing
cocrystal formation.
4.1. Supramolecular Analysis. In our previous manu-
script,22 we synthesized three 5-FC salts also using as coformers
Figure 5. (a) Crystal packing diagram of form B. Black dashed lines
indicate hydrogen bonds, (I) refers to the R2
2(8) motif37a,b involving
the N−H···N 5-FC homodimers and (II) R22(8) motif37a,b involving
the N−H···O 5-FC homodimers, (b) three-dimensional hydrogen-
bonded network of form B.
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dicarboxylic acids: fumaric, maleic, and oxalic. The structures
were obtained from the continuum to the salt part of the
spectrum, according to the pKa rule, where the ΔpKa value
ranged between 0 and positive values. Due the complementar-
ity among the carboxylic group and the functional groups
present in the 5-FC molecules, all the salts exhibited the same
R2
2(8) motif, constituting heterodimers, via N41−H41A···O4
and N3+−H3···O3− hydrogen bonds. The same supramolecular
synthon was observed for the salicylate of 5-FC, reported by
Portalone and Colapietro in 2007.20 On the other hand, when
we go to the other side of the spectrum, i.e., when weaker
dicarboxylic acids are used as coformers, changes occur in the
ionicity of the 5-FC molecule and new supramolecular
synthons overcome. According to Mukherjee and Desiraju,40
cocrystal formation is usually expected to occur when
heterosynthons are formed over homosynthons. However, for
the cocrystals of 5-FC with succinic, adipic, benzoic, and
terephtalic acids, instead of heterodimers we observe
homodimers occurring among the 5-FC molecules accessed
through complementary N41−H41···N3 and N1−H1···O21
hydrogen bonds. Nevertheless, for a ΔpKa very close to 0
(“cutoﬀ” among cocrystals and salts for this ﬂuoropyrimidine),
as in form M (ΔpKa = −0.1), a supramolecular transition
synthon is observed. In this cocrystal, the crystal packing still
preserves the heterodimer observed in the salts, except for the
fact that no proton transfer is observed, but also exhibits the
N1−H1···O21 homodimer among the 5-FC molecules. For this
homodimer, which is common in all cocrystals, the 5-FC
carbonyl bond lengths go from 1.265 to 1.249 Å. These values
are signiﬁcantly higher than the ones found for the 5-FC salts
(1.232 to 1.219 Å). It is clear that this feature is the result of the
protonation where the charge redistribution implies on a
reduction of the carbonyl bond lengths, which, in turn, does not
favor the geometric requirements for the formation of the
synthon needed for the establishment of the homodimers
present in the cocrystals. However, the geometric features of
the form M show intermediate values for the carbonyl bond
lengths, suggesting a partial charge redistribution that may lead
to a hybrid salt/cocrystal specie. Indeed, this form shows the
salts heterodimer synthon, even without protonation, possibly
due the intermediate strength of malic acid (pKa = 3.40). This
transition state becomes clearer when a correlation plot
between the variations of the C−O bond lengths in the
carboxylic fragments (ΔDC−O) of the coformers and the
variations of the C−N bond lengths (ΔDC−N) of the imidic
fragments of the 5FC ring is carried out (Figure 7). It is worth
mentioning that the fumarate salt of 5-FC22 (form F) is
hydrated, and the presence of water molecules in its crystal
packing result in changes in the intermolecular interaction
patterns leading to a diﬀerent behavior of the 5-FC intra-
molecular bond lengths approximating its ΔDC−N values to the
ones found for form M.
In an attempt to understand which changes occur in the 5-
FC molecule and consequently the speciﬁc supramolecular
patterns formed, the UNI Force Field Calculations, a tool of the
Mercury crystallography package,41,42 was used to establish and
compare the intermolecular potentials of the main interactions.
It is important to highlight that the purpose of this application
is to display those interactions between molecules which are
most signiﬁcant in energetic terms without performing the
computationally expensive lattice energy calculations. This
study allowed us to determine that in most of the cases the
potentials of the complementary N1H1···O21 hydrogen bonds
are the strongest ranging between −9.1 to −7.6 kcal/mol, with
the exception of form T and form M. Since this homodimer
was recurrent in all the cocrystals of 5-FC, this synthon can be
Figure 6. (a) Crystal packing diagram of form M. Black dashed lines
indicate hydrogen bonds, (I) refers to the R2
2(8) motif37a,b involving
the N−H···O 5-FC homodimers, (II) to the R22(8) motif
37a,b involving
the N−H···O and O−H···N 5-FC heterodimer, and (III) to the
R6
4(36) motif,37a,b (b) three-dimensional hydrogen-bonded network of
form M.
Figure 7. Correlation between the C−N bond length diﬀerences,
ΔDC−N, of the imidic group of 5-FC ring vs the C−O bond length
diﬀerences of the carboxylic fragments, ΔDC−O, evidencing the
intermediary interface between salts/cocrystals of form M. The
forms Ma, F, O, and EDATOS refer to the salts of 5-FC with maleic,
fumaric, oxalic, and salycilic acids.19,22
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Figure 8. Comparison of the supramolecular structure of diﬀerent 5-FC solid forms containing just neutral 5-FC molecules: (a) form S, (b) form A,
(c) form T, (d) form B, (e) form M, (f) cocrystal under refcode MECTUL,24 (g) solvate under refcode DUKWAI,17 (h) polymorph under refcode
MEBQEQ,15 (i) polymorph under refcode MEBQEQ01,15 (j) cocrystal under refcode MECXID,25 (k) cocrystal under refcode MECVUN,24 (l)
cocrystal under refcode MECWAU24 and (m) cocrystal under refcode MECWEY,24 (n) solvate under refcode MEBQOA,15 (o) solvate under
refcode MEBQIU,15 (p) cocrystal under refcode MECWUO,25 (q) cocrystal under refcode MECXEZ,25 (r) cocrystal under refcode MECVEX,24 (s)
cocrystal under refcode MECVIB,24 (t) cocrystal under refcode MECWOI,24 (u) solvate under refcode DUKWEM,17 (v) hydrates of 5-FC (I) under
refcodes BIRMEU,14 BIRMEU01,16 BIRMEU02,15 and (II) under refcode BIRMEU03,15 (w) hydrate under refcode PANLAS,18 (x) hydrated
cocrystal under refcode MECVOH,24 (y) hydrated cocrystal under refcode MECXOJ,25 (z) hydrate under refcode DUKWIQ,17 (1) hydrate under
refcode MEBQUG15 and (2) hydrated cocrystal under refcode GATMUL.23
Crystal Growth & Design Article
dx.doi.org/10.1021/cg500502j | Cryst. Growth Des. 2014, 14, 4383−43934389
considered a key piece in the assembly of the cocrystal packing.
On the other hand, the complementary N41−H41···N3
hydrogen bonds (present in the forms A, S, T, and B) show
smaller potential values ranging between −5.5 to −4.9 kcal/
mol. As previously discussed, form M represents an
intermediate state in the border of the salt−cocrystal
continuum. Instead of the N41−H41···N3 hydrogen bonds
present in the homodimers, we observed interactions occurring
among the 5-FC molecule and the malic acid one (N41−
H41B···O4 and O3−H3···N3), this heterosynthon being typical
of the organic acid salts.19,22 The potential value of this synthon
for form M is −9.7 kcal/mol, and this one is the highest
potential observed for all interactions present in this crystalline
form, showing that stronger acids have the ability of competing
for these interactions, thus replacing the weaker N−H···N ones.
In addition, the study of the intermolecular potentials also
allows us to evaluate the strength of the π···π interactions
between the layers formed by the 5-FC-acids units. These
interactions have potentials ranging from −9.6 to −4.9 kcal/
mol, agreeing in all the cases with the proximity of the layers in
the 3D supramolecular arrangements. A correlation is observed
between the energy of these interactions and the distance of the
layers. form M, which displays the closest distance between the
layers, also exhibits a high potential (−8.2 kcal/mol) for the
π···π interactions, whereas the highest potential observed to the
π···π interactions was between terephthalic acid units of form T
(−9.6 kcal/mol). All the potentials calculated are summarized
in Tables A7, B7...E77 (see the Supporting Information,
Sections A−E).
Extending our supramolecular study for the neutral 5-FC
molecules, a comparative analysis was performed on the basis of
all the crystalline structures already reported containing 5FC
molecules. Polymorphs, solvates, and cocrystals, plus mixtures
of them, such as solvated cocrystals, were also considered. 5-FC
is a rigid molecule and presents three potential patterns of
hydrogen bonding sites, two acceptor−donor involving the
atoms O21−N1 and N3−N41 (ON and NN, respectively), and
one acceptor−acceptor−donor involving the atoms O21−N3−
Table 2. Distribution of the Main Supramolecular Synthons Observed for the Diﬀerent 5-FC Solid Forms Containing Just
Neutral 5-FC
N−H···O, N−H···N N−H···O N−H···N
CG-like base
pairing
structurea homo hetero homo hetero homo hetero homo hetero planar cavity tubular cavity 5-FC ribbons
a √ √ √ √
b √ √ √ √
c √ √ √ √
d √ √ √ √
e √ √ √ √
f √ √
g √
h √ √
i √ √
j √ √ √
k √ √ √
l √ √ √ √
m √ √ √
n √ √ √
o √ √ √
p √ √ √
q √ √
r √ √ √ √
s √ √ √
t √ √
u √ √ √ √
v(I) √ √ √
v(II) √ √ √ √
w √ √ √
x √ √
y √ √
z √ √ √ √
1 √ √ √
2 √ √ √
aComparison of the supramolecular structure of diﬀerent 5-FC solid forms containing just neutral 5-FC molecules: (a) form S, (b) form A, (c) form
T, (d) form B, (e) form M, (f) cocrystal under refcode MECTUL,24 (g) solvate under refcode DUKWAI,17 (h) polymorph under refcode
MEBQEQ,15 (i) polymorph under refcode MEBQEQ01,15 (j) cocrystal under refcode MECXID,25 (k) cocrystal under refcode MECVUN,24 (l)
cocrystal under refcode MECWAU24 and (m) cocrystal under refcode MECWEY,24 (n) solvate under refcode MEBQOA,15 (o) solvate under
refcode MEBQIU,15 (p) cocrystal under refcode MECWUO,25 (q) cocrystal under refcode MECXEZ,25 (r) cocrystal under refcode MECVEX,24 (s)
cocrystal under refcode MECVIB,24 (t) cocrystal under refcode MECWOI,24 (u) solvate under refcode DUKWEM,17 (v) hydrates of 5-FC (I) under
refcodes BIRMEU,14 BIRMEU01,16 BIRMEU02,15 and (II) under refcode BIRMEU03,15 (w) hydrate under refcode PANLAS,18 (x) hydrated
cocrystal under refcode MECVOH,24 (y) hydrated cocrystal under refcode MECXOJ,25 (z) hydrate under refcode DUKWIQ,17 (1) hydrate under
refcode MEBQUG15 and (2) hydrated cocrystal under refcode GATMUL.23
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N41 (ONN). Tutughamiarso and co-workers17 showed that the
5-FC molecule, when neutral, tends to interact to one another
by self-complementary homodimers, constituting planar or
tubular 5-FC ribbons. These homodimers, as observed in the
cocrystals depicted here, are essentially composed by one N−
H···O and one N−H···N (ON/NN), or by two N−H···O
(ON/ON), or even by two N−H···N (NN/NN) intermo-
lecular interactions. Complementing this claim, Figure 8
exhibits a schematic drawing of the classical intermolecular
interactions of each reported structure considering the whole
supramolecular architecture adopted by the 5-FC molecules
under the diﬀerent crystalline arrangements. It shows that not
only ribbons are observed, but also planar and/or tubular
cavities, mainly due to the intrinsic geometry of the ON, NN,
ONN hydrogen bonding sites. Furthermore, Table 2 exhibits a
statistical analysis of the distribution of the main supra-
molecular synthons observed for the 5-FC molecule, including
homo- and heterodimers involving the three main hydrogen
bonding sites (ON/ON, ON/NN and NN/NN) plus the
formation of homo- and heterotrimers with hydrogen bonding
patterns similar to the CG Watson and Crick base pairing.
According to Table 2, the 5-FC molecule tends to form ON/
NN, ON/ON, and NN/NN homodimers. Tutughamiarso and
co-workers17 observed the particular NN/NN homodimer
formation only in the hydrate under refcode BIRMEU03,15
reporting later a cocrystal of 5-FC under refcode MECTUL24
also exhibiting this pattern of NN/NN homodimer formation.
The forms S, T, A, and B, however, exhibit the same ribbon
formation that occurs for the hydrate under refcode
BIRMEU03,15 i.e., ON/ON and NN/NN R2
2(8) motifs37a,b
per 5-FC molecule, while in the 5-FC cocrystal under refcode
MECTUL24 the free ON site of the 5-FC molecule is
intercepted by the formation of a ON/NN heterodimer with
the coformer molecule. In addition, two ON/NN (refcodes
MECVIB24 and e GATMUL23) and two ON/ON heterodimers
(refcodes MECWUO25 and GATMUL23) are observed.
However, no NN/NN heterodimer was reported until the
present.
On the other hand, for the ONN CG-like base pairing, the
tendency is the formation of heterosynthons with a total of nine
structures. Only in one hydrate (refcode PANLAS18) the C
G-like base pairing is observed between the 5-FC molecules. By
analyzing the crystalline packing of the 5-FC cocrystal under
refcode MECTUL24 (see Figure 8f), the occurrence of one
ON/NN heterodimer disrupts the 5-FC ribbon formation.
Although homoribbons (i.e., ribbons constituted only by 5-FC
molecules) are prevalent in most of the crystalline structures,
12 of them exhibit heteroribbons and all refer to cocrystals (2
cocrystals and 10 solvated cocrystals).
By considering the cavity formation, two exceptions arise,
one referring to the cocrystal under refcode MECTUL24
(Figure 8f), where ﬂat layers are stacked by van der Waals
contacts and one referring to the solvate under refcode
DUKWAI17 (Figure 8g), for which small cavities are observed
only when the nonclassical C−H···O and C−H···F intermo-
lecular interactions between the dimethyl sulfoxide and 5-FC
molecules are considered. Both reported polymorphs of 5-FC
exhibit tubular patterns (Figure 8h, (i), constituting R4
4(24) and
R6
4(26) motifs, involving four and six 5-FC molecules,
respectively. Forms S, A, and T (Figure 8a−c) exhibit similar
cavities, diﬀering only in their size (R6
4(40), R6
4(48), R6
4(44), for
forms S, A, and T, respectively), proportional to the size and
the geometry of each acid molecule. Figure 8h exhibits the last
planar cavity, R7
6(44), involving only solid coformers,
concerning the cocrystal under refcode MECXID.25 When
solvents are involved in the interactions, they lead to planar and
tubular cavities, for which it is not possible to establish a
speciﬁc pattern for these ternary systems. In particular, the
cocrystal under refcode MECVEX24 (Figure 8r) and the
hydrate under refcode DUKWIQ17 (Figure 8z) display cavities
of both tubular and planar types. It is worth mentioning that
the planar cavities of the methanol solvate under refcode
MEBQOA15 (Figure 8 (l)), of the cocrystal under refcode
MECVEX24 (Figure 8r) and of the hydrate under refcode
DUKWIQ17 (Figure 8z), are similar to the one formed in forms
S, A, and T. This shows that the recurrent supramolecular
synthon observed for the cocrystals depicted herein is not
restricted to the use of carboxylic acids as coformers. In this
way, it could be expected that new structures containing 5-FC
molecule can be designed and developed as new tailor-made
drugs.
4.2. Cocrystal of 5-FC and 5-FU. 5-Fluorouracil, 5-ﬂuoro-
2,4-(1H,3H)-pyrimidinedione, is an antineoplastic API ration-
ally designed by Heidelberger and co-workers in 1957.43 It is
used for the treatment of superﬁcial skin carcinomas as a cream
formulation and as injections in the treatment of various
cancers, including, among others, gastrointestinal, head and
neck, breast, colorectal, and ovarian. 5-FU is a synthetic
pyrimidine analogue and is probably the most widely used,
being of great interest in the clinical and experimental
chemotherapy among the developed analogues of purine and
pyrimidine, as it is structurally similar to natural bases.
Nevertheless, only a fraction of the administered amount of
this API becomes available in the systemic circulation after oral
administration due to its poor water solubility.44−46 Indeed,
oral delivery of antineoplastic APIs is considered a challenge
due their physical and chemical properties and physiological
barriers.47
As an illustration of a controlled rational supramolecular
synthesis of new solid forms of a given API using 5-FC as
coformer, we designed a cocrystal of 5-FC and 5-FU (form 5F,
pKa = 8.0).
44 It is clear that the 5-FU was our ﬁrst molecule of
choice for this example due to its structural similarities with 5-
FC. The cocrystallization experiment was developed according
to the pKa rule and a cocrystal was expected (ΔpKa = −4.74).
The aim of this particular experiment was to design a new solid
form of 5-FU with enhanced physical and chemical properties
that could enable this API to be orally administered together
with 5-FC, which in turn exhibits high solubility and
bioavailability proﬁles.10 However, the solubility properties of
form 5-FU are still under investigation.
The asymmetric unit of form 5F (see Figure 1) exhibits one
molecule of 5-FC and one of 5-FU. The main intermolecular
interactions responsible for maintaining the crystalline arrange-
ment of this cocrystal are of the types N−H···O and N−H···F
(see Table S1 in the Supporting Information section), including
the formation of homodimers of 5-FC (I, in Figure 9a),
homodimers of 5-FU (II, in Figure 9a) and intermolecular
interactions among the 5-FC and 5-FU molecules (Figure 9a).
Nonclassical intermolecular interactions are also present, as a
result of the close packing: C6−H6···F51 (bond distance of
2.467 Å), C6′−H6′···F51′ (bond distance of 2.354 Å), C6′−
H6′···N3 (bond distance of 2.639 Å), and C6−H6···O21′
(bond distance of 2.553 Å). The crystal packing of form 5F is
composed of ﬂat tapes in which the dimers are interspersed.
These tapes are stacked constituting columns with a parallel
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displaced arrangement (displacement angle of 23.2°), main-
tained by π···π interactions (5-FCπ···π = 3.5604(9) Å and 5-
FUπ···π = 3.5603(9)Å). Adjacent tapes (and consequently
adjacent columns) exhibit two directions of growth and are
connected to one another by intermolecular interactions
between the molecules of 5-FC and 5-FU, forming a dihedral
angle of 130.17(3)° (Figure 9b).
5. CONCLUSION
The 5-FC cocrystals with succinic, adipic, benzoic, and tereftalic
acids were obtained following the tendency of the pKa rule and
have revealed a similar hydrogen-bonding pattern, leading to 5-
FC ribbons, stabilized by two R2
2(8) motifs, characterized by
complementary homodimeric N−H···N (NN/NN) and N−
H···O (ON/ON) interactions, which was found to be a feature
of cocrystals containing this ﬂuoropyrimidine molecules.
Analyzing the supramolecular characteristics of the four 5-FC
cocrystals (together with some similar structures reported in
the literature), it was observed that the 5-FC molecule tends to
form ON/NN, ON/ON, and NN/NN homodimers, ONN
CG-like base pairing heterotrimers, and both tubular and
planar cavities. Nevertheless, when the cocrystallization experi-
ment was conducted with malic acid, where the ΔpKa = −0.1, a
supramolecular transition synthon was observed, in which the
N−H···O homodimeric synthon present in the cocrystals
remains, but a new heterodimeric synthon, characterized by
complementary N−H···O hydrogen bonds between the 5-FC
molecule and the malic acid, emerged. This last synthon was
found in the 5-FC organic salts, obtained even from very small
positive ΔpKa values (such as for the fumarate of 5-FC where
ΔpKa = 0.23). The discovery of this transition synthon
indicates that the 5-FC molecule is a suitable candidate for
the design and development of cocrystallization experiments
based on crystal engineering techniques, once its behavior
could be, until the present, well predicted by the pKa rule. To
check our hypothesis, we conducted a cocrystallization
experiment of 5-FC with the antineoplastic drug 5-FU, aiming
to obtain a cocrystal once the system exhibits a ΔpKa = −3.0.
The success of this experiment points to a new path to apply 5-
FC as a coformer in new controlled crystallization experiments
for the development of new tailor-made drugs.
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